Cargando…

Effectiveness and safety of VISULAS(®) green selective laser trabeculoplasty: a prospective, interventional multicenter clinical investigation

PURPOSE: To evaluate the effectiveness and safety of Selective Laser Trabeculoplasty (SLT) with the SLT mode of the VISULAS(®) green laser in patients with primary open-angle glaucoma (POAG). METHODS: This prospective, interventional multicenter clinical investigation included patients with POAG who...

Descripción completa

Detalles Bibliográficos
Autores principales: Pillunat, Karin R., Kretz, Florian T. A., Koinzer, Stefan, Ehlken, Christoph, Pillunat, Lutz E., Klabe, Karsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313537/
https://www.ncbi.nlm.nih.gov/pubmed/36572747
http://dx.doi.org/10.1007/s10792-022-02617-7
_version_ 1785067147949506560
author Pillunat, Karin R.
Kretz, Florian T. A.
Koinzer, Stefan
Ehlken, Christoph
Pillunat, Lutz E.
Klabe, Karsten
author_facet Pillunat, Karin R.
Kretz, Florian T. A.
Koinzer, Stefan
Ehlken, Christoph
Pillunat, Lutz E.
Klabe, Karsten
author_sort Pillunat, Karin R.
collection PubMed
description PURPOSE: To evaluate the effectiveness and safety of Selective Laser Trabeculoplasty (SLT) with the SLT mode of the VISULAS(®) green laser in patients with primary open-angle glaucoma (POAG). METHODS: This prospective, interventional multicenter clinical investigation included patients with POAG who either needed a treatment escalation because the individual intraocular pressure (IOP) target was not met or treatment initiation and had an IOP ≥ 17 mmHg at baseline in the study eye. The study was conducted in five research centers across Germany. Approximately 100 laser applications were delivered to 360° of the trabecular meshwork. Glaucoma medications were not modified during the 3-month follow-up to allow evaluation of the sole effect of VISULAS(®) green with SLT. Efficacy outcomes were postoperatively absolute and relative IOP changes at 1 and 3 months. Safety outcomes analyzed the rate of intra- and postoperative adverse events. RESULTS: Thirty-four eyes of 34 POAG patients were included. The overall mean number of preoperative glaucoma medications was 2.2 ± 1.4 in 29 treated eyes, 5 eyes were treatment naïve. Mean baseline IOP (mmHg) was 21.0 ± 2.69 and was reduced by − 3.53 ± 3.34 [95% CI − 4.61; − 2.45] and − 3.59 ± 3.41 [95% CI − 4.64; − 2.53] at the 1- and 3-month follow-up, respectively (p < 0.0001), with 48.5% of cases achieving a ≥ 20% IOP reduction at 3 months [95% CI = 30.8%; 66.5%]. The mean relative IOP reduction was − 16.4% and − 16.3% at 1 and 3 months, respectively (p < 0.0001). Potentially device- or procedure-related adverse events were mild to moderate and included 3 postoperative IOP-spikes and 6 reports regarding eye pain and discomfort. All were resolved without sequelae. CONCLUSIONS: SLT performed with the VISULAS(®) green laser achieved clinically significant additional IOP reductions in medically treated as well as in treatment naïve eyes with POAG and there were no relevant safety issues. The results are comparable to other reported SLT studies.
format Online
Article
Text
id pubmed-10313537
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-103135372023-07-02 Effectiveness and safety of VISULAS(®) green selective laser trabeculoplasty: a prospective, interventional multicenter clinical investigation Pillunat, Karin R. Kretz, Florian T. A. Koinzer, Stefan Ehlken, Christoph Pillunat, Lutz E. Klabe, Karsten Int Ophthalmol Original Paper PURPOSE: To evaluate the effectiveness and safety of Selective Laser Trabeculoplasty (SLT) with the SLT mode of the VISULAS(®) green laser in patients with primary open-angle glaucoma (POAG). METHODS: This prospective, interventional multicenter clinical investigation included patients with POAG who either needed a treatment escalation because the individual intraocular pressure (IOP) target was not met or treatment initiation and had an IOP ≥ 17 mmHg at baseline in the study eye. The study was conducted in five research centers across Germany. Approximately 100 laser applications were delivered to 360° of the trabecular meshwork. Glaucoma medications were not modified during the 3-month follow-up to allow evaluation of the sole effect of VISULAS(®) green with SLT. Efficacy outcomes were postoperatively absolute and relative IOP changes at 1 and 3 months. Safety outcomes analyzed the rate of intra- and postoperative adverse events. RESULTS: Thirty-four eyes of 34 POAG patients were included. The overall mean number of preoperative glaucoma medications was 2.2 ± 1.4 in 29 treated eyes, 5 eyes were treatment naïve. Mean baseline IOP (mmHg) was 21.0 ± 2.69 and was reduced by − 3.53 ± 3.34 [95% CI − 4.61; − 2.45] and − 3.59 ± 3.41 [95% CI − 4.64; − 2.53] at the 1- and 3-month follow-up, respectively (p < 0.0001), with 48.5% of cases achieving a ≥ 20% IOP reduction at 3 months [95% CI = 30.8%; 66.5%]. The mean relative IOP reduction was − 16.4% and − 16.3% at 1 and 3 months, respectively (p < 0.0001). Potentially device- or procedure-related adverse events were mild to moderate and included 3 postoperative IOP-spikes and 6 reports regarding eye pain and discomfort. All were resolved without sequelae. CONCLUSIONS: SLT performed with the VISULAS(®) green laser achieved clinically significant additional IOP reductions in medically treated as well as in treatment naïve eyes with POAG and there were no relevant safety issues. The results are comparable to other reported SLT studies. Springer Netherlands 2022-12-26 2023 /pmc/articles/PMC10313537/ /pubmed/36572747 http://dx.doi.org/10.1007/s10792-022-02617-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Paper
Pillunat, Karin R.
Kretz, Florian T. A.
Koinzer, Stefan
Ehlken, Christoph
Pillunat, Lutz E.
Klabe, Karsten
Effectiveness and safety of VISULAS(®) green selective laser trabeculoplasty: a prospective, interventional multicenter clinical investigation
title Effectiveness and safety of VISULAS(®) green selective laser trabeculoplasty: a prospective, interventional multicenter clinical investigation
title_full Effectiveness and safety of VISULAS(®) green selective laser trabeculoplasty: a prospective, interventional multicenter clinical investigation
title_fullStr Effectiveness and safety of VISULAS(®) green selective laser trabeculoplasty: a prospective, interventional multicenter clinical investigation
title_full_unstemmed Effectiveness and safety of VISULAS(®) green selective laser trabeculoplasty: a prospective, interventional multicenter clinical investigation
title_short Effectiveness and safety of VISULAS(®) green selective laser trabeculoplasty: a prospective, interventional multicenter clinical investigation
title_sort effectiveness and safety of visulas(®) green selective laser trabeculoplasty: a prospective, interventional multicenter clinical investigation
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313537/
https://www.ncbi.nlm.nih.gov/pubmed/36572747
http://dx.doi.org/10.1007/s10792-022-02617-7
work_keys_str_mv AT pillunatkarinr effectivenessandsafetyofvisulasgreenselectivelasertrabeculoplastyaprospectiveinterventionalmulticenterclinicalinvestigation
AT kretzflorianta effectivenessandsafetyofvisulasgreenselectivelasertrabeculoplastyaprospectiveinterventionalmulticenterclinicalinvestigation
AT koinzerstefan effectivenessandsafetyofvisulasgreenselectivelasertrabeculoplastyaprospectiveinterventionalmulticenterclinicalinvestigation
AT ehlkenchristoph effectivenessandsafetyofvisulasgreenselectivelasertrabeculoplastyaprospectiveinterventionalmulticenterclinicalinvestigation
AT pillunatlutze effectivenessandsafetyofvisulasgreenselectivelasertrabeculoplastyaprospectiveinterventionalmulticenterclinicalinvestigation
AT klabekarsten effectivenessandsafetyofvisulasgreenselectivelasertrabeculoplastyaprospectiveinterventionalmulticenterclinicalinvestigation